Table 1 Demographic and clinical characteristics of total study population and PJP patients.
From: Risk factors for Pneumocystis jirovecii pneumonia (PJP) in kidney transplantation recipients
Characteristics | N = 500 |
|---|---|
Sex, N (%) | |
Men | 307 (61.4) |
Women | 193 (38.6) |
Age, years (median, range) | 47 (18–71) |
Transplantation era, N (%) | |
2011.4–2012.3 | 167 (33.4) |
2012.4–2013.3 | 158 (31.6) |
2013.4–2014.4 | 175 (35.0) |
BMI, kg/m2 (median, IQR) | 22 (20.1–24.2) |
KT type, N (%) | |
Deceased | 178 (35.6) |
Living | 322 (64.4) |
Re-transplantation, N (%) | 41 (8.2) |
Primary underlying disease, N (%) | |
Polycystic kidney | 17 (3.4) |
HTN | 198 (39.6) |
DM | 85 (17.0) |
IgA nephropathy | 63 (12.6) |
Autoimmune disease | 7 (1.4) |
Chronic glomerulonephritis | 36 (7.2) |
Nephrotic syndrome | 41 (8.2) |
Recurrent pyelonephritis/other | 21 (4.2) |
Unknown | 32 (6.4) |
Immunosuppressive agent, N (%) | |
Cyclosporine based regimen | 60 (12.0) |
Tacrolimus based regimen | 440 (88.0) |
Follow up duration, month (median, range) | 36.2 (18.4–54.5) |
Development of PJP, N (%) | 18 (3.6) |
Interval between PJP and graft, month (median IQR) | 17.4 (11.2–27.9) |
−12 month, N (%) | 4 (22.2) |
12–24 month, N (%) | 7 (38.9) |
24–36 month, N (%) | 6 (33.3) |
36- month, N (%) | 1 (5.6) |
Treatment medication of PJP, N (%) | |
TMP-SMX alone | 13 (72.2) |
TMP-SMX prior to primaqiune + clinadamycin | 4 (22.2) |
TMP-SMX prior to pentamidine | 1 (5.6) |
